Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.190 -0.220 (-9.13%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Is It Too Late to Buy Intellia Therapeutics? ↗

July 10, 2021

After skyrocketing 68% last week, will this stock keep running higher?

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 06, 2021

Gainers Advaxis (NASDAQ:ADXS) shares increased by 43.13% to $0.68 during Tuesday's regular session. The current volume of 106.3 million shares is 1084.49% of Advaxis...

Via Benzinga

Here's What Drove Gene Editing Stocks Higher This Week ↗

July 02, 2021

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Via The Motley Fool

Unusual Options Activity Insight: Editas Medicine ↗

July 01, 2021

Shares of Editas Medicine (NASDAQ:EDIT) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $53.28. Sentiment:...

Via Benzinga

Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar ↗

June 30, 2021

Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.

Via InvestorPlace

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

72 Biggest Movers From Yesterday ↗

July 01, 2021

Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...

Via Benzinga

Topics Initial Public Offering

Why Gene Editing Stocks Are Trading Higher Again Today ↗

June 30, 2021

Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...

Via Benzinga

51 Stocks Moving In Wednesday's Mid-Day Session ↗

June 30, 2021

Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6...

Via Benzinga

Why Editas Medicine Stock Is Jumping Today ↗

June 28, 2021

Good news for Intellia was viewed as good news for Editas.

Via The Motley Fool

Intellia Stock Leads Biotech Rally On Historic Moment For CRISPR ↗

June 28, 2021

Intellia led a rally for CRISPR stocks on Monday on early promise for its gene-editing drug. The news sent NTLA stock to a record high.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 28, 2021

Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 62.0% to $143.91 during Monday's pre-market session. The company's market cap stands at $9.8 billion....

Via Benzinga

Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks ↗

June 28, 2021

Gene editing stocks, led by NTLA stock, are powering higher on Monday following a landmark announcement by Intellia Therapeutics.

Via InvestorPlace

Why Editas Medicine Stock Is Jumping 13.9% This Week ↗

June 25, 2021

The company received a go-ahead to enroll kids in a study of its lead gene-editing candidate.

Via The Motley Fool

What's the Best Way to Invest in Genetics Stocks? ↗

June 07, 2021

Here are some of our experts' favorite gene editing plays for the long run.

Via The Motley Fool

Is Editas the Best Genetics Stock to Buy? ↗

June 05, 2021

There are some big opportunities in the gene editing space.

Via The Motley Fool

Earnings Roundup: General Motors, Editas Medicine, Activision Blizzard, Match Group ↗

May 17, 2021

What we're learning during earnings season.

Via The Motley Fool

Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript ↗

May 05, 2021

EDIT earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

What Really Mattered With Editas Medicine's Q1 Update ↗

May 05, 2021

It wasn't the biotech's financial performance.

Via The Motley Fool

Best Biotech Stocks & ETFs for mRNA, Gene Editing ↗

April 29, 2021

2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space.

Via Talk Markets

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021 ↗

May 04, 2021

Upgrades For Genuine Parts Co (NYSE:GPC), Goldman Sachs upgraded the previous rating of Sell to Neutral. In the first quarter, Genuine Parts showed an EPS of $1.50,...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 23, 2021

Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 11.8% to $1.61 during Friday's pre-market session. The market value of their outstanding shares is at $205....

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 19, 2021

Gainers INmune Bio (NASDAQ:INMB) stock rose 26.18% to $13.59 during Monday's regular session. As of 08:06 EST, this security is trading at a volume of 560.6K shares,...

Via Benzinga

54 Biggest Movers From Friday ↗

April 19, 2021

Gainers Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares surged 73.9% to close at $31.30 on Friday after the company priced its IPO at $18 per share. General Finance...

Via Benzinga

Topics Initial Public Offering

CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today ↗

April 16, 2021

A "sell" rating is one thing, but a 50% price target? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.

Via InvestorPlace

Nasdaq Stays Flat as Workhorse Drives Higher, Editas Sinks ↗

April 16, 2021

Investors are trying to figure out which stocks have the best prospects.

Via The Motley Fool

Topics Stocks

Why Editas Medicine Stock Is Getting Crushed Today ↗

April 16, 2021

Investors are running for the hills following this analyst take on the biotech's prospects.

Via The Motley Fool

38 Stocks Moving In Friday's Mid-Day Session ↗

April 16, 2021

Gainers Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares jumped 78.1% to $32.06 after the company priced its IPO at $18 per share. General Finance Corporation (NASDAQ: GFN)...

Via Benzinga

Topics Initial Public Offering

Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021 ↗

April 16, 2021

Upgrades According to Argus Research, the prior rating for United Airlines Holdings Inc (NASDAQ:UAL) was changed from Hold to Buy. In the fourth quarter, United Airlines...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.